Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.39
- Piotroski Score 3.00
- Grade Overweight
- Symbol (TNDM)
- Company Tandem Diabetes Care, Inc.
- Price $30.82
- Changes Percentage (0.26%)
- Change $0.08
- Day Low $30.00
- Day High $31.26
- Year High $53.69
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $58.00
- High Stock Price Target $160.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.16
- Trailing P/E Ratio -22.62
- Forward P/E Ratio -22.62
- P/E Growth -22.62
- Net Income $-222,611,000
Income Statement
Quarterly
Annual
Latest News of TNDM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tandem Diabetes Care, Inc. (TNDM): Should You Add This Diabetes Stock To Your Portfolio Now?
The article explores the growth of diabetes stocks, with a focus on Tandem Diabetes Care, Inc. (NASDAQ:TNDM). The market for diabetes care products is expanding rapidly, particularly for continuous gl...
By Yahoo! Finance | 3 months ago -
Tandem Diabetes Care, Inc. (TNDM) Stock Price, News, Quote & History - Yahoo Finance
Tandem Diabetes Care develops innovative technology solutions for diabetes management, including insulin delivery systems and data management platforms. Founded in 2006, the company is based in San Di...
By Yahoo! Finance | 3 months ago -
Tandem Diabetes Care, Inc. (TNDM) Stock Price, News, Quote & History
Tandem Diabetes Care, Inc. is a medical device company that offers innovative technology solutions for diabetes management worldwide, including the t:slim X2 insulin delivery system and Tandem Mobi in...
By Yahoo! Finance | 3 months ago
